425: PowerUp Acquisition Corp. Agrees to $1 Million Fee for Sponsor's Risk in Terminated Visiox Deal

PowerUp Acquisition Corp. will pay its sponsor, SRIRAMA Associates, LLC, a $1 million fee upon the successful closing of the Aspire Biopharma business combination to compensate for the risk taken in a prior, terminated deal with Visiox Pharmaceuticals.

Summary

• PowerUp Acquisition Corp. (PWUP) has entered into a Promissory Note Fee Agreement with its sponsor, SRIRAMA Associates, LLC.
• This agreement compensates the sponsor for the risk it took by providing a $2 million bridge loan to Visiox Pharmaceuticals via a convertible promissory note.
• The original agreement stipulated a $2 million fee to the sponsor upon the successful closing of the business combination between PWUP and Visiox.
• However, PWUP terminated the business combination agreement with Visiox on July 22, 2024, thus terminating the sponsor's right to the original fee.
• Under the new agreement, PWUP will pay the sponsor a modified fee of $1 million upon the successful closing of a business combination with Aspire Biopharma, Inc.
• The agreement was made effective as of October 2, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the agreement provides clarity on sponsor compensation, it also highlights a failed deal and a potentially controversial payment.

Positives

• The agreement provides clarity and compensation to the sponsor for the risk taken in the initial Visiox deal.
• The modified fee is lower than the original fee, potentially saving the company $1 million.
• The agreement is contingent on the successful closing of the Aspire Biopharma business combination, aligning the sponsor's interests with the company's success.

Negatives

• The company is incurring a $1 million expense to compensate the sponsor for a deal that did not materialize.
• This payment could be viewed negatively by investors as it relates to a failed transaction.

Risks

• The successful closing of the Aspire Biopharma business combination is required for the payment of the $1 million fee.
• Failure to close the Aspire Biopharma deal would mean the sponsor is not compensated for the risk taken in the Visiox deal.
• There is a risk of potential legal challenges or shareholder scrutiny regarding the fairness of the $1 million fee.

Future Outlook

The company's future outlook is tied to the successful completion of the business combination with Aspire Biopharma, which will trigger the payment of the $1 million fee to the sponsor.

Management Comments

• SPAC acknowledged that Sponsor took significant risk on behalf of SPAC by entering into the Visiox Promissory Note, and that Sponsor should be compensated for that risk despite the termination of the right to receive the Original Promissory Note Fee as a result of the termination of the Visiox BCA.

Industry Context

SPACs often rely on sponsors to provide initial capital and expertise, and it is not uncommon for sponsors to receive compensation for their efforts. However, the payment of a fee for a terminated deal may raise concerns about corporate governance and the alignment of interests between the sponsor and shareholders.

Comparison to Industry Standards

• Sponsor compensation in SPAC deals varies widely, but typically includes equity stakes and fees upon completion of a business combination.
• The $1 million fee represents a significant portion of the initial capital provided by the sponsor.
• Comparable companies such as Gores Group and Churchill Capital often negotiate similar compensation structures with their sponsors.
• However, it is unusual to see a fee paid for a terminated deal, which may raise questions about the fairness of the arrangement.

Related Party Transactions

• The Promissory Note Fee Agreement is a related party transaction as it involves the company and its sponsor.

Stakeholder Impact

• Shareholders may be concerned about the payment of a fee for a terminated deal.
• The sponsor benefits from the agreement as it receives compensation for the risk taken in the Visiox deal.

Next Steps

• The company will need to successfully close the business combination with Aspire Biopharma to trigger the payment of the $1 million fee.
• The company will need to disclose the details of the Promissory Note Fee Agreement in its financial statements.

Key Dates